16:37 , Jan 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Stroke Mouse studies suggest inhibiting signaling between RTN4R, RTN4RL2 and their ligands could help treat white matter stroke. In a mouse model of the disease, white matter levels of three negative regulators of Nogo signaling...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Oxford Molecular other research news

A European consortium led by OMG received a £450,000 (US$756,000) Eureka grant from the U.K. Department of Trade and Industry to develop a library of software that will be delivered without charge on the Internet....
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Oxford Molecular, Astra Group AB deal

Astra’s Astra Arcus AB subsididary (Sodertajle) and OMG will develop an integrated set of desktop software tools to define, store, retrieve and analyze data in the drug discovery process. The companies plan to complete the...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Oxford Molecular, MLR Automation deal

OMG will acquire MLR, a developer of data management software for high throughput screening, for $2.5 million. OMG plans to finance the acquisition through a 1 for 7 rights issue (see B19). OMG paid $75,000...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Oxford Molecular, Genetics Computer Group Inc. deal

OMG will acquire Genetics Computer Group, a developer of software for DNA and protein sequence analysis, for $20 million. OMG plans to finance the acquisition through a 1 for 7 rights issue (see B19). OMG...
07:00 , Sep 27, 2010 |  BioCentury  |  Emerging Company Profile

Axerion: Going beyond NOGO

While several companies are working on approaches to stimulating axonal regrowth for conditions caused or characterized by nerve damage, Axerion Therapeutics Inc. believes its NGR receptor decoys will more potently treat conditions such as acute...
07:00 , May 27, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Reticulon 4 (RTN4; NOGO-A; NOGO); myelin-associated glycoprotein (MAG); oligodendrocyte myelin glycoprotein (OMG; OMGP); reticulon...
08:00 , Dec 4, 2008 |  BC Innovations  |  Cover Story

New strategies for CNS regeneration

Two separate teams of company and university researchers have identified multiple neuronal proteins that could be targeted alone or in combination to promote axon growth and treat spinal cord injury and other forms of CNS...
07:00 , Sep 11, 2000 |  BC Week In Review  |  Company News

Oxford Molecular, Pharmacopeia deal

PCOP completed its acquisition of OMG bioinformatics and cheminformatics software subsidiaries Oxford Molecular Ltd., Chemical Holding Designs plc and Oxford Molecular Group Inc. for $27 million in cash (see BioCentury, Aug. 14). Oxford Molecular Group...
07:00 , Aug 14, 2000 |  BC Week In Review  |  Company News

Oxford Molecular, Pharmacopeia deal

OMG will sell its software solutions businesses to PCOP for $27 million in cash. The sale includes Oxford Molecular Ltd., Chemical Design Holdings plc and Oxford Molecular Group Inc., which develop and market bioinformatics...